Ranibizumab 产品活性：Ranibizumab (RG-6321) 是一种人源化的抗 VEGF 单克隆抗体片段，能够识别所有 VEGF-A 亚型 (VEGF110，VEGF121，以及 VEGF165)。动物模型中，Ranibizumab 减缓视力丧失，并用于老年黄斑变性 (AMD) 的研究。 产品来源： https://www.medchemexpress.cn/ranibizumab.html 研究领域：Protein Tyrosine Kinase/RTK 作用靶点：VEGFR In Vitro: Ranibizumab (RG-6321) is a humanized anti-VEGF monoclonal antibody fragment (IgG antigen-binding fragment (Fab-Y0317). Ranibizumab (0.0625-0.25 mg/ml; 72 hours) results in increased necrosis and apoptosis at in rat retinal cell cultures. In Vivo: Studies in monkeys demonstrates that after a single intravitreal administration, Ranibizumab can distribute rapidly to the retina (6–24?h). Ranibizumab can rapidly penetrate through the retina to reach the choroid, just 1?h after intravitreal administration in rabbits.In a study comparing the pharmacokinetics of 0.5?mg of intravitreal Ranibizumab with 1.25?mg of intravitreal Bevacizumab (HY-P9906) in the rabbit, the vitreous half-life of Ranibizumab is 2.88 days, shorter than the Bevacizumab half-life of 4.32 days. Peak concentrations in the aqueous humor of the treated eye at 3 days following treatment are 37.7?μg/ml for Bevacizumab?and 17.9?μg/ml for Ranibizumab, respectively. 相关产品：Sorafenib | Lenvatinib | Bevacizumab | Regorafenib | Sunitinib | Nintedanib | Semaxinib | Cabozantinib | Ponatinib | Axitinib | Midostaurin | Chloramphenicol | Pazopanib | Glycine | PD173074 | Tanshinone IIA | Fruquintinib | 5Z-7-Oxozeaenol | Vandetanib | SU 5402 | Linifanib | Foretinib | SPHINX31 | Ripretinib | GW806742X | Dovitinib 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。